Vinge has represented the international private equity firm Cinven in connection with its acquisition of the Säkra group (“Säkra”).

Säkra, with about 350 insurance professionals across 60 offices throughout Sweden, provides tailor-made insurance solutions, occupational pension plans and advisory services, and is one of the leading insurance intermediaries in Sweden. The acquisition of Säkra marks the fourth investment from Cinven’s inaugural Strategic Financials Fund (‘SFF’).

The SFF builds on Cinven’s leading financial services investment platform in Europe with an investment strategy focused on areas where Cinven has developed significant investment expertise, such as life and non-life insurance and reinsurance, asset-backed speciality finance, wealth management, insurance distributors and other ‘capital light’ tech-enabled financial service providers.

The acquisition is subject to approvals from the Swedish Financial Supervisory Authority and the Swedish Competition Authority.

Vinge's team consisted mainly of Christina Kokko, Samra Baytar, Carl Fredrik Wachtmeister and Robin Fagerström (M&A), Viveka Classon and Fabian Ekeblad (Corporate Insurance), Emma Stuart-Beck, Caroline Krassén, Henrik Schön and David Flodin (Financial Services), Hedvig Ekdahl (Commercial Agreements), Kristoffer Larsson (Real Estate), Louise Brorsson Salomon, Kamyar Najmi and Ellen Flygt (Banking and Finance), Rebecka Målquist (IP), Nicklas Thorgerzon (IT and GDPR) Sara Strandberg (Employment), David Olander and Victoria Fredén (ECR), and Emy Rydén (project assistant).

 

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025